Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (42): 7847-7850.doi: 10.3969/j.issn.1673-8225.2011.42.014

Previous Articles     Next Articles

Preparation and characteristics of gentamicin sulfate-loaded chitosan nanospheres

Li Liang-liang, Wang Li-ming, Xu Yan   

  1. Department of Orthopedics, Nanjing First Hospital, Nanjing Medical University, Nanjing 210001, Jiangsu Province, China
  • Received:2011-04-05 Revised:2011-05-11 Online:2011-10-15 Published:2011-10-15
  • Contact: Wang Li-ming, Master, Professor, Department of Orthopedics, Nanjing First Hospital, Nanjing Medical University, Nanjing 210001, Jiangsu Province, China
  • About author:Li Liang-liang★, Studying for master’s degree, Department of Orthopedics, Nanjing First Hospital, Nanjing Medical University, Nanjing 210001, Jiangsu Province, China creto007@163.com

Abstract:

BACKGROUND: Gentamicin beads as a local drug delivery system was earlier used for the treatment of chronic osteomyelitis of the local drug delivery system, but due to its degradation and absorption in the body, it cannot be the second out, thus its application is limited. Therefore, domestic and foreign scholars have been working to study absorbable materials loaded with antibiotics device.
OBJECTIVE: To formulate the gentamicin sulfate-loaded chitosan nanospheres (GS-CS nanospheres) and to evaluate its performance and to study its releasing behavior and the anti-staph aureus efficacy in vitro.
METHODS: The GS-CS nanospheres were prepared by ion cross-linking technique using chitosan as drug carrier and gentamicin sulfate as model drug and sodium tripolyphosphate as crosslinker reagent. The drug loading and encapsulation efficiency were estimated. The releasing behavior of the GS-CS nanospheres was studied and the diameter of inhibition zone of the GS-CS nanospheres was measured.
RESULTS AND CONCLUSION: The nanospheres were spherical with the diameter ranging from 40 nm to 70 nm, the encapsulation efficiency and drug loading were estimated to be 31.3% and 15.4%, respectively. In vitro releasing behavior could continue about 14 days; the anti-staph aureus efficacy in vitro could continue about 25 days, the greatest anti-staph aureus efficacy reached at 5 days and then decreased gradually.

CLC Number: